Vyant Bio, Inc.

VYNT

Explore Our Financial Data > Companies > Services > Vyant Bio, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	VYNT
CIK	0001349929
SIC	8071
Sector	Services
Industry Category	Healthcare
Industry Group	Services – Health

Contact

Address	2370 STATE ROUTE 70 WEST, SUITE 310, CHERRY HILL,, NJ, 08002
Website	vyantbio.com
Phone	201.528.9200
CEO	John A. Roberts
Employees	30

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$666,000.00
Pre-Tax Income	$-15.81 million
Net Income	$-22.69 million
Net Income to Common	$-22.69 million
EPS	N/A

View All

Balance Sheet

Cash	$10.04 million
Assets	$13.66 million
Liabilities	$5.02 million
Common Equity	$9.91 million
Liabilities & Equity	$14.93 million

View All

Cash Flow Statement

Net Income	$-22.69 million
Cash From Operating Activities	$-13.68 million
Cash From Investing Activities	$3.26 million
Cash From Financing Activities	$-149,000.00
Change in Cash	$-10.57 million

View All

Calculations

NOPAT	$-11.14 million
EBITDA	$-15.06 million
Price to Earnings	N/A
Price to Book	$0.12
ROE	-110.15%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Vyant Bio Provides Update on Winddown Activities

CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company’s stock will cease trading on t

Article Link

Vyant Bio Provides Update on Winddown Activities

CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company’s common stock will cease to trade and

Article Link

Vyant Bio Announces Stockholder Approval of Plan of Dissolution

CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”). At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the “Dissolu

Article Link

Lab Notes: Philadelphia health care investment firm closes two funds valued at over $500M

This week's roundup of life sciences news from across the Philadelphia region includes updates from 1315 Capital, the Pennsylvania Biotechnology Center and Vyant Bio.

Article Link

Vyant Bio Announces Completion of StemoniX Asset Sale

CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to an Asset Purchase Agreement dated July 13, 2023. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (OTC: VYNT) has no continuing operating activities other than the winddown and closure of its business. The Company is currently seeking to obtain its shareholders’ approval for the

Article Link